Incidence and Prevalence of Multiple Sclerosis in the Americas: A Systematic Review

Abstract

Background: The incidence and prevalence of multiple sclerosis (MS) varies considerably around the world. No previous study has performed a comprehensive review examining the incidence and prevalence of MS across the Americas. The purpose of this study was to systematically review and assess the quality of studies estimating the incidence and/or prevalence of MS in North, Central and South American regions. Methods: A comprehensive literature search was performed using MEDLINE and EMBASE from January 1985 to January 2011. Search terms included ‘multiple sclerosis’, ‘incidence’, ‘prevalence’ and ‘epidemiology’. Only full-text articles published in English or French were included. Study quality was assessed using an assessment tool based on recognized guidelines and designed specifically for this study. Results: A total of 3,925 studies were initially identified, with 31 meeting the inclusion criteria. The majority of studies examined North American regions (n = 25). Heterogeneity was high among all studies, even when stratified by country. Only half of the studies reported standardized rates, making comparisons difficult. Quality scores ranged from 3/8 to 8/8. Conclusion: This review highlights the gaps that still exist in the epidemiological knowledge of MS in the Americas, and the inconsistencies in methodologies and quality among the published studies. There is a need for future studies of MS prevalence and incidence to include uniform case definitions, employ comparable methods of ascertainment, report standardized results, and be performed on a national level. Other factors such as sex distribution, ethnic make-up and population lifestyle habits should also be considered.

The burden of neurological disease in the United States: A summary report and call to action

“…33 Women are 2 to 3 times more likely to develop MS, and it is more common in younger adults, peaking around age 30 years, the beginning of the most productive work and family years. Direct medical costs were estimated at $26,631 per MS patient for the year 2011, but may be much higher now, as considerably more expensive drugs have been developed and deployed widely over the past 5 years.…”

Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts

“…[1][2][3][4] It is the most common non-traumatic disabling neurological condition among young Tweet this article adults in Canada. 5 Onset is typically between the ages of 20 and 40 years, and women are affected more often than men.…”

“…1,5 Although the etiology of MS remains unknown, genetic predisposition and environmental factors jointly trigger the disease. 2,6 The prevalence of MS varies geographically, and high-prevalence areas include Canada, the northern United States, most of northern Europe, New Zealand, southeastern Australia and Israel. 7 The prevalence of MS in Canada is among the highest worldwide.…”

The Associations Between Fatigue, Disability, and Mobility and the Quality of Life in Patients with Multiple Sclerosis

“…The incidence and prevalence of MS varies considerably around the world (9). In Iran, the prevalence of MS varies from 15 to 30 per 100 thousand people (10), which continues to grow (11).…”